Cite
HARVARD Citation
Afonso, M. et al. (2017). Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain. Journal of medical economics. pp. 633-639. [Online].